Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
This article was originally published in The Tan Sheet
The impact of forced Rx-to-OTC switches on consumers "is uncertain and ambiguous and there is no clear gain in social welfare," MIT economics professor Ernst Berndt, PhD, says in recent comments to FDA
You may also be interested in...
FDA should evaluate whether OTC Claritin has increased access and lowered costs for allergy sufferers before deciding whether to require the other second-generation antihistamines to switch OTC, Pfizer asserts in May 7 comments to the agency
Perrigo promotes in pricing, planning
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC